Literature DB >> 20051697

The interaction of the neuroprotective compounds riluzole and phenobarbital with AMPA-type glutamate receptors: a patch-clamp study.

Ling-Jing Jin1, Friedrich Schlesinger, Yun-Ping Song, Reinhard Dengler, Klaus Krampfl.   

Abstract

BACKGROUND: Blockade of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-type glutamate receptors is a promising pharmacological strategy in the treatment of neurodegenerative diseases. The aim of the study is to elucidate if there are direct interactions of riluzole and phenobarbital with AMPA-type receptor channels and to determinethe molecular pharmacological mechanisms.
METHODS: The patch-clamp technique was used combining an ultrafast solution exchange system to investigate the interaction of riluzole and phenobarbital with recombinant AMPA-type glutamate receptor channels (homomeric GluR2flipGQ or nondesensitizing GluR2L504Y).
RESULTS: A dose-dependent decrease in the relative peak current amplitude (rAmp) and the relative area-under-the-current curve (rAUC) were found after preincubation with 0.1 mmol/l or higher concentrations of riluzole. Furthermore, in coapplication experiments with GluR2L504Y, the application of 1 or 3 mmol/l riluzole showed a decrease in the current decay time constant, and a reopening current was observed at 3 mmol/l riluzole. Phenobarbital blocks AMPA receptor channels dose-dependently in the coapplication experiments, and reopening currents after removing glutamate and blocker were observed. A slight block effect after preincubation should indicate an additional competitive block effect.
CONCLUSION: Riluzole and phenobarbital modulate AMPA-type receptor channels separately, which could be both characterized as a combination of open-channel block and competitive-block mechanism. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20051697     DOI: 10.1159/000268641

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  5 in total

1.  Use of antiepileptic drugs for hyperkinetic movement disorders.

Authors:  A Siniscalchi; L Gallelli; G De Sarro
Journal:  Curr Neuropharmacol       Date:  2010-12       Impact factor: 7.363

2.  Phenobarbital but Not Diazepam Reduces AMPA/kainate Receptor Mediated Currents and Exerts Opposite Actions on Initial Seizures in the Neonatal Rat Hippocampus.

Authors:  Romain Nardou; Sumii Yamamoto; Asma Bhar; Nail Burnashev; Yehezkel Ben-Ari; Ilgam Khalilov
Journal:  Front Cell Neurosci       Date:  2011-07-28       Impact factor: 5.505

3.  Gacyclidine improves the survival and reduces motor deficits in a mouse model of amyotrophic lateral sclerosis.

Authors:  Yannick N Gerber; Alain Privat; Florence E Perrin
Journal:  Front Cell Neurosci       Date:  2013-12-27       Impact factor: 5.505

Review 4.  Secondary Epileptogenesis: Common to See, but Possible to Treat?

Authors:  Yujia Shen; Yiwei Gong; Yeping Ruan; Zhong Chen; Cenglin Xu
Journal:  Front Neurol       Date:  2021-12-06       Impact factor: 4.003

5.  Human amyotrophic lateral sclerosis excitability phenotype screen: Target discovery and validation.

Authors:  Xuan Huang; Kasper C D Roet; Liying Zhang; Amy Brault; Allison P Berg; Anne B Jefferson; Jackie Klug-McLeod; Karen L Leach; Fabien Vincent; Hongying Yang; Anthony J Coyle; Lyn H Jones; Devlin Frost; Ole Wiskow; Kuchuan Chen; Rie Maeda; Alyssa Grantham; Mary K Dornon; Joseph R Klim; Marco T Siekmann; Dongyi Zhao; Seungkyu Lee; Kevin Eggan; Clifford J Woolf
Journal:  Cell Rep       Date:  2021-06-08       Impact factor: 9.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.